


dAURK-4 hydrochloride

Cat. No.: HY-137344A
Molecular Formula: C₅₂H₅₃Cl₂FN₈O₁₂
Molecular Weight: 1071.93
Target: Aurora Kinase
Pathway: Cell Cycle/DNA Damage; Epigenetics
Storage: -20°C, sealed storage, away from moisture
 * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 66.67 mg/mL (62.20 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	
				5 mg	
				10 mg	
			1 mg	5 mg	10 mg
	1 mM		0.9329 mL	4.6645 mL	9.3290 mL
	5 mM		0.1866 mL	0.9329 mL	1.8658 mL
	10 mM		0.0933 mL	0.4664 mL	0.9329 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 5 mg/mL (4.66 mM); Suspended solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	dAURK-4 hydrochloride, an Alisertib derivative, is a potent and selective AURKA (Aurora A) degrader. dAURK-4 hydrochloride has anticancer effects ^[1] .	
IC ₅₀ & Target	Aurora A	
In Vitro	dAURK-4 (125-1000 nM; 4-24 hours) hydrochloride shows degradation of AURKA in a dose-dependent manner ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1]	
	Cell Line:	MM.1S cells
	Concentration:	125 nM, 250 nM, 500 nM, 1000 nM
	Incubation Time:	4 hours or 24 hours

Result:

Inhibited the protein level of AURKA (Aurora A).

REFERENCES

[1]. Katherine A Donovan, et al. Mapping the Degradable Kinome Provides a Resource for Expedited Degradar Development. Cell. 2020 Dec 10;183(6):1714-1731.e10.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA